Live Breaking News & Updates on Cell Transplant Centre
Stay updated with breaking news from Cell transplant centre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hyderabad varsity startup develops stem cell-based treatment for Covid Top Searches: IANS | Updated: May 4, 2021, 09:46 IST A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients. Picture used for representational purpose only HYDERABAD: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients. Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. ....
Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics, a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday. The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients. ....
Hyderabad-based Startup Develops Stem Cell Therapy for COVID by Angela Mohan on May 4, 2021 at 9:45 AM Adult Mesenchymal Stem Cells (MSCs)-based therapy may hold potential in treating COVID-19 positive patients. Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 cytokine storm , with significantly improved patient survival and time to recovery. The research recommends HEMATO UC-MSCs to be administered as two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients . ....
HYDERABAD: A novel stem cell based treatment for Covid-19 patients, developed by a startup incubated at the University of Hyderabad, has emerged as an alternative for treatment of the virus. The biotech startup, Transcell Oncologics, announced a cell based technology Hemato human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) that has anti-inflammatory and repairing properties. “From donated umbilical cord tissues, we have harvested and clinically processed adult MSCs that upon infusion in the patient s body would reduce cytokine storm (a protein) produced by the virus. They decrease the inflammation in the patient’s body triggered by the virus,” said Dr Subadra Dravida, founder chief executive officer, Transcell. ....
UoH startup develops stem cell-based treatment for COVID-19 By IANS| Posted by Neha | Updated: 3rd May 2021 11:15 pm IST University of Hyderabad Hyderabad: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for COVID-19 patients. Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 ‘cytokine storm’, with significantly improved patient survival and time to recovery. ....